AIM BREAKFAST – 3rd August 2016
Set Menu AIM:
Total number of AIM Companies (Incl Susp): 1,015
Total number of AIM Companies trading: 990*
* As at 30 June 2016
Dish of the Day:
No Primary Today
No Primary Today
Off the Menu:
No Leavers Today
No Leavers Today
Set Menu ISDX Growth:
Total number of ISDX Growth Market Companies (Incl Susp): *
Total number of ISDX Growth Market Companies trading: *
* As at 30 June 2016
Dish of the Day:
Off the Menu:
What’s Cooking in the IPO Kitchen?
Franchise Brands (FRAN.L) confirmed it will join AIM on Friday. £3.5m raise at 33p oversubscribed. 15.6m market cap. Currently focusses on car paintwork repair and domestic cleaning. 2015 – £4.4m rev/£1.1m PBT
The Intertain Group Ltd – World’s largest online bingo-led operator (on TSX) intends to join Official List
Autins Group plc – The acoustic and thermal insulation specialist looks to join AIM early August
Sareum Holdings* (SAR.L) 0.69p £18.12m
The specialist cancer drug discovery and development business has announced that the Chinese Patent Office and the Hong Kong Patents Registry have issued notifications that patents will be granted for inventions associated with Sareum’s Aurora+FLT3 Kinase Inhibitor Programme. Similar patents have previously been granted in the USA and Europe. The programme has shown efficacy against acute myeloid leukaemia in disease models and in collaboration with its partner, preclinical studies are underway with a view to human trials.
Conroy Gold and Natural Resources* (CGNR.L) 36.5p £4.02m
The gold exploration and development Company has released the results of its first drill hole from the current programme at the flagship Clay Lake-Clontibret gold target in Ireland, where the Company has an exploration target of 5 million oz. gold. It included high grade gold intersections of 1 metre at 15g/t gold and 1 metre at 8.4g/t gold and the discovery of a new gold bearing lode. This follows the recent intersection of four new gold zones at its Glenish target.
Venn Life Sciences Holdings* (VENN.L) 28p £16.9m
The growing Contract Research Organisation (CRO) has signed a new contract worth €2.8m with a European Biotechnology client. The clinical trial is a Phase II study in the area of Immunotherapeutic treatments for Multiple Sclerosis and commences in October 2016. Furthermore Venn’s Interactive Response Technology (“IRT”) department, has successfully qualified as a service provider to a top ten Pharmaceutical client and been awarded an initial 36 site project in China.
MedaPhor Group (MED.L) 39.5p £10.76m
The provider of advanced ultrasound skills training simulators for medical professionals has announced H1Jun2016 results. Sales +17% to £1.26m. Operating loss flat at £1m. Cash balances of £3.5m. The Company has also announced the £3m all share acquisition of Inventive Medical (IML), plus £2.7m of shareholder loans. Benefits of the acquisition include a complementary suite of ultrasound training products and enlarged revenues. For the year ended 31 March 2015 IML recorded audited revenue of £1.9m and a loss before tax of £0.3m.
Mi-Pay Group (MPAY.L) 23.5p £9.77m
The provider of outsourced and fully managed digital transformation and mobile payment solutions to Tier 1 Mobile Network Operators and Mobile Virtual Network Operators has provided a H1Jun2016 trading update. Transactions processed up 34% to £39m. Expected revenue of £1.6m vs £1.5m. Gross profit up 33% to £1m and £0.6m operating loss improvement to £0.2m. Cash above management expectations at £3.4m as at 30 June. FY transaction values expected to be circa £80m vs £65m. Progressing well towards cash flow break even.
TechFinancials (TECH.L) 29p £5.83m
The technology provider to financial trading brokers has provided an H1Jun2016 trading update. Revenue has increased by over 30% from US$7.34 million in the first half of 2015 to in excess of US$9.6 million during the first half of 2016. Additionally, operating performance improved substantially compared with the same period in 2015, resulting in EBITDA increasing by over 80% from US$0.55 million to in excess of US$1 million. Consensus sterling forecasts project FY revenues of £15.13m and EPS of 0.65p.
Telit Communications (TCM.L) 266.75p £306.5m
The global enabler of the Internet of Things (IoT), has signed a multi-faceted collaboration agreement with Tech Mahindra Ltd (NSE: TechM, “Tech Mahindra”), a specialist in digital transformation, consulting and business re-engineering, to develop end-to-end solutions for the IoT. Telit and Tech Mahindra are already engaged in several industrial customer projects together, including a leading global heavy equipment company.
Science in Sport (SIS.L) 55p £23.8m
The sports nutrition company that develops, manufactures and markets sports nutrition products for professional athletes and sports enthusiasts, announces that it finalised an agreement to become the Official Sports Nutrition Supplier to USA Cycling (‘USAC’), the official governing body for all disciplines of competitive cycling in the United States. This is a good win following the company’s expansion into the US. Consensus forecasts are looking for FY2016 revenues of £12m and a pre-tax loss of £0.99m
Red24 (REDT.L) 24.5p £12.1m
The crisis assistance company has responded to an announcement by iJet regarding a potential 24p per share offer for Red24. Red24 advises shareholders to take no action at this time and emphasises that discussions are at a preliminary stage. The shares trade on 10.6x consensus earnings for FYMar2017 and have a projected yield of 2.4%.
StatPro Group (SOG.L) 99p £64.1m
The provider of portfolio analysis and asset pricing services for the global asset management industry, has published its interim results for the six months ended 30 June 2016. Group revenue up 14% to £17.55 million. Adjusted EBITDA increased by 19% to £2.05 million. Interim dividend maintained at 0.85 pence per share. Fwd order book of contracted revenue increased 19% to £44.13 million (2015: £37.01 million), 8% on a constant currency basis. Your chef will attend the 0930 analyst meeting.
0203 764 2344
*A corporate client of Hybridan LLP
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific entity and is not a personal recommendation to anyone. Recipients should make their own investment decisions based upon their own financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, they have not been independently verified and are not guaranteed as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information in this document nor should it be relied upon as such.
Any and all opinions expressed are current opinions as of the date appearing on this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, does not constitute “independent investment research” for the purposes of the Financial Conduct Authority rules. The individuals who prepared this document may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, directors, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the UK, this document is directed at and is for distribution only to persons who (i) fall within Article 19(5) (persons who have professional experience in matters relating to investments) or Article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) or (ii) are Professional Clients or Eligible Counterparties (as those terms are defined in the rules of the Financial Conduct Authority) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as “relevant persons”). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by persons who would be classified as Retail Clients (as defined by the rules of the Financial Conduct Authority).
Neither this document nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of UK or US securities law, or the law of any such other jurisdictions.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, directors, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
Neither the whole nor any part of this document may be duplicated in any form or by any means. Neither should this document, or any part thereof, be redistributed or disclosed to anyone without the prior consent of Hybridan LLP.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX. If you would like to unsubscribe, please email firstname.lastname@example.org with “unsubscribe me”.